Raffaella Gesuete1, Sara N Christensen1, Frances R Bahjat1, Amy E B Packard1, Susan L Stevens1, Mingyue Liu1, Andres M Salazar1, Mary P Stenzel-Poore2. 1. From the Department of Molecular Microbiology and Immunology, Oregon Health and Sciences University, Portland, OR (R.G., S.N.C., F.R.B., A.E.B.P., S.L.S., M.L., M.P.S.-P.); and Oncovir, Washington, DC (A.M.S.). 2. From the Department of Molecular Microbiology and Immunology, Oregon Health and Sciences University, Portland, OR (R.G., S.N.C., F.R.B., A.E.B.P., S.L.S., M.L., M.P.S.-P.); and Oncovir, Washington, DC (A.M.S.). poorem@ohsu.edu.
Abstract
BACKGROUND AND PURPOSE: Preconditioning with poly-l-lysine and carboxymethylcellulose (ICLC) provides robust neuroprotection from cerebral ischemia in a mouse stroke model. However, the receptor that mediates neuroprotection is unknown. As a synthetic double-stranded RNA, poly-ICLC may bind endosomal Toll-like receptor 3 or one of the cytosolic retinoic acid-inducible gene-I-like receptor family members, retinoic acid-inducible gene-I, or melanoma differentiation-associated protein 5. Activation of these receptors culminates in type I interferons (IFN-α/β) induction-a response required for poly-ICLC-induced neuroprotection. In this study, we investigate the receptor required for poly-ICLC-induced neuroprotection. METHODS: Toll-like receptor 3, melanoma differentiation-associated protein 5-, and IFN-promoter stimulator 1-deficient mice were treated with poly-ICLC 24 hours before middle cerebral artery occlusion. Infarct volume was measured 24 hours after stroke to identify the receptor signaling pathways involved in protection. IFN-α/β induction was measured in plasma samples collected 6 hours after poly-ICLC treatment. IFN-β-deficient mice were used to test the requirement of IFN-β for poly-ICLC-induced neuroprotection. Mice were treated with recombinant IFN-α-A to test the role of IFN-α as a potential mediator of neuroprotection. RESULTS: Poly-ICLC induction of both neuroprotection and systemic IFN-α/β requires the cytosolic receptor melanoma differentiation-associated protein 5 and the adapter molecule IFN-promoter stimulator 1, whereas it is independent of Toll-like receptor 3. IFN-β is not required for poly-ICLC-induced neuroprotection. IFN-α treatment protects against stroke. CONCLUSIONS: Poly-ICLC preconditioning is mediated by melanoma differentiation-associated protein 5 and its adaptor molecule IFN-promoter stimulator 1. This is the first evidence that a cytosolic receptor can mediate neuroprotection, providing a new target for the development of therapeutic agents to protect the brain from ischemic injury.
BACKGROUND AND PURPOSE: Preconditioning with poly-l-lysine and carboxymethylcellulose (ICLC) provides robust neuroprotection from cerebral ischemia in a mousestroke model. However, the receptor that mediates neuroprotection is unknown. As a synthetic double-stranded RNA, poly-ICLC may bind endosomal Toll-like receptor 3 or one of the cytosolic retinoic acid-inducible gene-I-like receptor family members, retinoic acid-inducible gene-I, or melanoma differentiation-associated protein 5. Activation of these receptors culminates in type I interferons (IFN-α/β) induction-a response required for poly-ICLC-induced neuroprotection. In this study, we investigate the receptor required for poly-ICLC-induced neuroprotection. METHODS:Toll-like receptor 3, melanoma differentiation-associated protein 5-, and IFN-promoter stimulator 1-deficient mice were treated with poly-ICLC 24 hours before middle cerebral artery occlusion. Infarct volume was measured 24 hours after stroke to identify the receptor signaling pathways involved in protection. IFN-α/β induction was measured in plasma samples collected 6 hours after poly-ICLC treatment. IFN-β-deficient mice were used to test the requirement of IFN-β for poly-ICLC-induced neuroprotection. Mice were treated with recombinant IFN-α-A to test the role of IFN-α as a potential mediator of neuroprotection. RESULTS:Poly-ICLC induction of both neuroprotection and systemic IFN-α/β requires the cytosolic receptor melanoma differentiation-associated protein 5 and the adapter molecule IFN-promoter stimulator 1, whereas it is independent of Toll-like receptor 3. IFN-β is not required for poly-ICLC-induced neuroprotection. IFN-α treatment protects against stroke. CONCLUSIONS:Poly-ICLC preconditioning is mediated by melanoma differentiation-associated protein 5 and its adaptor molecule IFN-promoter stimulator 1. This is the first evidence that a cytosolic receptor can mediate neuroprotection, providing a new target for the development of therapeutic agents to protect the brain from ischemic injury.
Authors: Raffaella Gesuete; Amy E B Packard; Keri B Vartanian; Valerie K Conrad; Susan L Stevens; Frances R Bahjat; Tao Yang; Mary P Stenzel-Poore Journal: J Neurochem Date: 2012-11 Impact factor: 5.372
Authors: Angela Dann; Hendrik Poeck; Andrew L Croxford; Stefanie Gaupp; Katrin Kierdorf; Markus Knust; Dietmar Pfeifer; Cornelius Maihoefer; Stefan Endres; Ulrich Kalinke; Sven G Meuth; Heinz Wiendl; Klaus-Peter Knobeloch; Shizuo Akira; Ari Waisman; Gunther Hartmann; Marco Prinz Journal: Nat Neurosci Date: 2011-12-04 Impact factor: 24.884
Authors: Amy E B Packard; Jason C Hedges; Frances R Bahjat; Susan L Stevens; Michael J Conlin; Andres M Salazar; Mary P Stenzel-Poore Journal: J Cereb Blood Flow Metab Date: 2011-11-16 Impact factor: 6.200
Authors: Wouter B Veldhuis; Sarah Floris; Peter H van der Meide; Ine M P Vos; Helga E de Vries; Christien D Dijkstra; Peter R Bär; Klaas Nicolay Journal: J Cereb Blood Flow Metab Date: 2003-09 Impact factor: 6.200
Authors: Wouter B Veldhuis; Joris W Derksen; Sarah Floris; Peter H Van Der Meide; Helga E De Vries; Janneke Schepers; Ine M P Vos; Christien D Dijkstra; L Jaap Kappelle; Klaas Nicolay; Peter R Bär Journal: J Cereb Blood Flow Metab Date: 2003-09 Impact factor: 6.200
Authors: Ernest C Borden; Ganes C Sen; Gilles Uze; Robert H Silverman; Richard M Ransohoff; Graham R Foster; George R Stark Journal: Nat Rev Drug Discov Date: 2007-12 Impact factor: 84.694